Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 10/20 | 0.33 |
| ▸ | WDR77 | Q9BQA1 | 8/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23523775 | 1.00 | GSK3B (0.42) | GSK3BDYRK1AHDAC6PRKCIPRMT5 | |
| SCHEMBL23523920 | 0.92 | KDM1A (0.36) | GSK3BHDAC6PRMT5WDR77EGLN2 | |
| SCHEMBL30355442 | 0.92 | KDM1A (0.36) | GSK3BHDAC6PRMT5WDR77EGLN2 | |
| SCHEMBL30355424 | 0.89 | GSK3B (0.33) | GSK3BPRMT5WDR77CDK1PRKCQ | |
| SCHEMBL23524171 | 0.89 | BRD4 (0.37) | GSK3BCDK1PRKCQMAP3K1BRD4 | |
| SCHEMBL30355385 | 0.89 | BRD4 (0.37) | GSK3BCDK1PRKCQMAP3K1BRD4 | |
| SCHEMBL23523727 | 0.89 | GSK3B (0.33) | GSK3BPRMT5WDR77CDK1PRKCQ | |
| SCHEMBL23524381 | 0.88 | GSK3B (0.34) | GSK3BCDK1PRKCQMAP3K1BRD4 | |
| SCHEMBL30355734 | 0.88 | GSK3B (0.34) | GSK3BCDK1PRKCQMAP3K1BRD4 | |
| SCHEMBL23524235 | 0.87 | GSK3B (0.43) | GSK3BDYRK1AHDAC6PRKCICDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | TREVENA, INC. | 2023-07-27 | — | — | US | disclosed |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | TREVENA, INC. | 2023-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234946-A1 | COMPOUNDS FOR MODULATING S1P1 ACTIVITY AND METHODS OF USING THE SAME | S1PR1, S1PR2, S1PR3 | GSK3B 2521/4885DYRK1A 2547/4885HDAC6 2041/4885 |
| US-20230114241-A1 | METHODS OF TREATING EPILEPSY USING THE SAME | S1PR1, S1PR2, S1PR3 | GSK3B 1281/4885DYRK1A 2933/4885HDAC6 856/4885 |
| US-11912693-B2 | Compounds for modulating S1P1 activity and methods of using the same | S1PR1, S1PR2, S1PR3 | GSK3B 2521/4885DYRK1A 2547/4885HDAC6 2041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.